Silexion Therapeutics Corp (SLXN)
NASDAQ: SLXN · Real-Time Price · USD
1.830
-0.070 (-3.68%)
Aug 5, 2026, 11:43 AM EDT - Market open
Silexion Therapeutics Employees
As of December 31, 2025, Silexion Therapeutics had 14 total employees, including 13 full-time and 1 part-time employees. The number of employees did not change compared to the previous year.
Employees
14
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$922,143
Market Cap
766.76K
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 14 | 0 | - | 13 | 1 |
| Dec 31, 2024 | 14 | - | - | 11 | 3 |
Related Stocks
| Company Name | Employees |
|---|---|
| Valion Bio | 52 |
| Jaguar Health | 47 |
| Scinai Immunotherapeutics | 45 |
| Calidi Biotherapeutics | 29 |
| Moleculin Biotech | 17 |
| VivoSim Labs | 15 |
| Genprex | 13 |
| Biodexa Pharmaceuticals | 11 |
SLXN News
- 1 day ago - Silexion Therapeutics Reports New Positive Preclinical Findings Demonstrating Multi-Mechanism Immune Sensitization by SIL204 in KRAS-Driven Cancers - GlobeNewsWire
- 6 days ago - Silexion Therapeutics downgraded at Maxim on delisting and dilution risk - TheFly
- 6 days ago - Silexion Therapeutics downgraded to Hold from Buy at Maxim - TheFly
- 7 days ago - Silexion Therapeutics initiates SIL204 trial - TheFly
- 7 days ago - Silexion Therapeutics Successfully Initiates Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer at Tel Aviv Sourasky Medical Center - GlobeNewsWire
- 6 weeks ago - Silexion Therapeutics Receives Approval from Germany's BfArM to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer - GlobeNewsWire
- 7 weeks ago - Silexion Therapeutics to Attend BIO International Convention 2026 - GlobeNewsWire
- 7 weeks ago - Silexion Therapeutics files to sell 859,609 ordinary shares for holders - TheFly